Fulgent Genetics (FLGT) Capital Expenditures (2015 - 2026)

Fulgent Genetics has disclosed Capital Expenditures across 12 years of filings, most recently posting $5.2 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $5.2 million, up 10.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.1 million (down 43.73% YoY), and the FY2025 annual result was $22.6 million, down 44.01% from the prior year.
• Capital Expenditures came in at $5.2 million for Q1 2026 at Fulgent Genetics, down from $20.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $37.8 million in Q4 2024 to a low of -$2.3 million in Q3 2024.
• The 5-year median for Capital Expenditures is $4.7 million (2025), against an average of $6.4 million.
• Across the five-year window, Capital Expenditures surged 1117.87% in 2024 and slumped 393.95% in 2025, its largest moves.
• Fulgent Genetics' Capital Expenditures stood at $4.7 million in 2022, then plunged by 34.22% to $3.1 million in 2023, then soared by 1117.87% to $37.8 million in 2024, then sank by 45.8% to $20.5 million in 2025, then tumbled by 74.63% to $5.2 million in 2026.
• The last three Capital Expenditures figures came in at $5.2 million (Q1 2026), $20.5 million (Q4 2025), and -$510000.0 (Q3 2025), per Business Quant data.